Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/1781
Назив: | The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation | Аутори: | Rančić N. Vavić N. Cikota-Aleksić B. Magić Z. Momir Mikov Bokonjić D. Šegrt Z. Dragojević-Simić V. |
Кључне речи: | kidney transplantation;tacrolimus;dose-response relationship;genetic;polymorphism | Датум издавања: | 1-феб-2018 | Часопис: | Vojnosanitetski Pregled | Сажетак: | © 2018, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Background/Aim. Tacrolimus concentration-dose ratio as a potential therapeutic drug monitoring strategy was suggested to be used for the patients subjected to renal trans-plantation. The aim of this study was examining the relationship between tacrolimus concentration-dose ratio, suggested to be used as a therapeutic drug monitoring strategy and the polymorphisms of genes encoding the most important enzymes, such as CYP3A5 and CYP3A4, as well as the transporter P-glycoprotein, for its metabolism and elimination. Methods. The study was designed as a prospective case series study, in which the unit of monitoring was the outpatient examination of 54 patients subjected to renal transplantation. Genotyping was performed by 7500 Real-Time PCR System by assessing allelic discrimination based on TaqMan® methodology. Results. Patients (n = 13) who were treated with less than 2 mg of tacrolimus/day (0.024 ± 0.006 mg/kg/day) had the tacrolimus concentration-dose ratio larger than 150 ng/mL/mg/kg. In this group, 84.62% patients had CYP3А5 *3*3 allele. All of these patients had CYP3А4 *1*1/*1*1B allele. Regarding ABCB1 C3435T gene, 30.77% of patients had the TT gene variant, while 69.23% of our patients had CC and CT gene variants. Conclusion. Tacrolimus concentration-dose ratio greater than 150 ng/mL/mg/kg is cut-off value in patients subjected to renal transplantation which might point to patients who are poor CYP3A5 metabolizers and/or with dysfunctional P-glycoprotein. | URI: | https://open.uns.ac.rs/handle/123456789/1781 | ISSN: | 428450 | DOI: | 10.2298/VSP151230329R |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
2
проверено 06.05.2023.
Преглед/и станица
24
Протекла недеља
7
7
Протекли месец
0
0
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.